Endocannabinoids and nicotine regulate the neurotransmitter release in different central and peripheral synapses. Various studies in the literature demonstrate the interaction between endocannabinoid ...and nicotinic systems, especially in the central nervous system. The interaction between nicotinic and endocannabinoid systems was investigated in this study. We aimed to show the effects of cannabinoid and vanilloid receptor antagonists on nicotine-induced relaxation response increases in rabbit corpus cavernosum.
From a total of seven male albino rabbits, three or four equal strips were cut from each corpus cavernosum and inserted in isolated organ baths. Tissues were contracted with phenylephrine (3×10
M). After contraction reached a plateau, strips were stimulated with EFS, and with the stabilization of EFS relaxation responses, 10
M of nicotine was administered to tissues. After that, in order to investigate the effects of AM251 (CB
antagonist), AM630 (CB
inverse agonist) or capsazepine (a vanilloid receptor antagonist) were given to different tissues, after the resting period.
Nicotine (10
M) increased the EFS-induced relaxation responses (14.60%±2.94%,
<0.05). AM630 decreased the enhancement of nicotine-induced EFS relaxation responses (nicotine 10
M enhancement: 17.16%±3.19%; nicotine 10
M enhancement in the presence of AM630 10
M: 4.44%±3.43%
<0.05; n=6), whereas effects of AM251 and capsazepine were not significant.
In the present study, nicotine increased the amplitudes of EFS-induced relaxation responses probably via nicotinic acetylcholine receptors located on the nitrergic nerves of the corpus cavernosum. We showed the role of cannabinoid-like endo-ligands in nicotine-induced enhancement via CB
receptors but not CB
and VR
receptors.
The endocannabinoid system plays important roles in various systems, including the genitourinary system; however, its mechanism of action is not fully understood.
This study aimed to investigate the ...direct relaxant effects of anandamide and its possible mechanisms in isolated rat bladder and vas deferens tissues.
Twenty-one adult male Wistar albino rats were used. Bladder and vas deferens (prostatic and epididymal portions) tissues were mounted in 10 mL of organ baths. Relaxation responses to anandamide were recorded at 3 and 10 μM concentrations. After the rest period, the procedures were repeated in the presence of cannabinoid (CB) and vanilloid receptor antagonists, various potassium channel blockers, cyclo-oxygenase, and nitric oxide synthase inhibitors. In different tissues to investigate the Ca
-channel antagonistic effect of anandamide, concentration-response curves to CaCl
were obtained in the absence and presence of anandamide.
Anandamide caused a significant relaxation response in the bladder and epididymal vas deferens tissues, but not in the prostatic portion. The effect of anandamide was antagonized in the presence of the CB
antagonist AM251 or the non-selective potassium channel blocker tetraethylammonium in bladder tissue. In the epididymal vas deferens, anandamide significantly inhibited the calcium contraction responses, especially at high concentrations. The CB
antagonist AM630 reversed this inhibition.
The results show that anandamide has a direct relaxant effect on the isolated rat bladder and epididymal vas deferens. Anandamide triggers different mechanisms in different types of tissues, and further studies are needed to elucidate the mechanism of action of anandamide.
Circadian rhythms are biological rhythms that originate from the “master circadian clock,” called the suprachiasmatic nucleus (SCN). SCN orchestrates the circadian rhythms using light as a chief ...zeitgeber, enabling humans to synchronize their daily physio-behavioral activities with the Earth’s light-dark cycle. However, chronic/ irregular photic disturbances from the retina via the retinohypothalamic tract (RHT) can disrupt the amplitude and the expression of clock genes, such as the period circadian clock 2, causing circadian rhythm disruption (CRd) and associated neuropathologies. The present review discusses neuromodulation across the RHT originating from retinal photic inputs and modulation offered by endocannabinoids as a function of mitigation of the CRd and associated neuro-dysfunction. Literature indicates that cannabinoid agonists alleviate the SCN’s ability to get entrained to light by modulating the activity of its chief neurotransmitter, i.e., γ-aminobutyric acid, thus preventing light-induced disruption of activity rhythms in laboratory animals. In the retina, endocannabinoid signaling modulates the overall gain of the retinal ganglion cells by regulating the membrane currents (Ca2+, K+, and Cl- channels) and glutamatergic neurotransmission of photoreceptors and bipolar cells. Additionally, endocannabinoids signalling also regulate the high-voltage-activated Ca2+ channels to mitigate the retinal ganglion cells and intrinsically photosensitive retinal ganglion cells-mediated glutamate release in the SCN, thus regulating the RHT-mediated light stimulation of SCN neurons to prevent excitotoxicity. As per the literature, cannabinoid receptors 1 and 2 are becoming newer targets in drug discovery paradigms, and the involvement of endocannabinoids in light-induced CRd through the RHT may possibly mitigate severe neuropathologies.
•Circadian rhythms originate from suprachiasmatic nucleus using light as a chief zeitgeber.•Cannabinoid agonists alleviate SCN’s ability entrained by light by modulating neuro-activity.•Endocannabinoids modulate retinal ganglion cells by Ca2+, K+, and Cl- channels and bipolar cells.•Endocannabinoids in light-induced CRd through retino-hypothalamic tract mitigate neuropathologies.•In SCN, endocannabinoids modulate glutamate release via retinohypothalamic tract, rescuing CRd.
The endocannabinoid system and prostaglandins are important modulators in the genitourinary system. This study aimed to investigate the possible interactions between the endocannabinoid system and ...the cyclooxygenase (COX) pathway on rat vas deferens. For this purpose, the concentration responses of the endocannabinoid anandamide, prostaglandin F
2α
analog latanoprost, and prostaglandin E
1
analog misoprostol on the electrical field stimulation (EFS)-induced contractile responses were obtained. The concentration responses to anandamide were obtained again in the presence of nonselective COX inhibitor flurbiprofen and prostaglandin analogs, while the concentration responses of latanoprost and misoprostol were obtained in the presence of cannabinoid receptor antagonists and fatty acid amide hydrolase (FAAH) enzyme inhibitor URB597. FAAH, COX-1, and COX-2 enzyme levels in vas deferens tissue samples were also determined. The cumulative addition of anandamide was not different from the vehicle; however, the EFS-induced contractile responses were significantly increased with the incubation of latanoprost or flurbiprofen in the prostatic portion. Flurbiprofen and misoprostol decreased FAAH enzyme levels in both portions of the vas deferens, while latanoprost induced the inhibition in the prostatic portion. The cumulative administration of latanoprost and misoprostol significantly enhanced the contractile responses in the prostatic portion. This effect of latanoprost was significantly antagonized by URB597 and AM251. The enhancing effect of misoprostol was antagonized by anandamide, URB597, AM251, and AM630. Anandamide, AM251, AM630, and URB597 decreased enzyme levels of COX-1 and COX-2 in both portions of the vas deferens. These results demonstrate an intricate crosstalk between endocannabinoids and prostaglandins in modulation of the vas deferens contractility.
Background
Protocatechuic acid is an antioxidant which is shown to have analgesic activity in limited studies. However, the mechanisms of action remain unclear.
Objectives
It is aimed to investigate ...the possible contribution of cannabinoid system that supresses the nociceptive process by the activation of CB1 and CB2 receptors in central and peripheral levels of pain pathways, to the analgesic activity of protocatechuic acid.
Methods
The analgesic activity of protocatechuic acid was determined at the doses of 75, 150 and 300 mg/kg (
i.p.
) by acetic acid-induced writhing and tail-immersion tests in mice. The results were compared to the analgesic effect of 300 mg/kg (
i.p.
) dipyrone and non-specific CB receptor agonist 5 mg/kg (
i.p.
) WIN 55,212–2. For investigating the contribution of cannabinoid system to protocatechuic acid analgesia; pre-treatment with 8 mg/kg (
i.p.
) CB1 antagonist AM251 and 8 mg/kg (
i.p.
) CB2 antagonist AM630 were performed separately before 300 mg/kg protocatechuic acid administration.
Results
It was determined that protocatechuic acid has dose-dependent analgesic effect independently from locomotor activity and is comparable with effects of dipyrone and WIN 55,212–2. Pre-treatment with CB1 receptor antagonist AM251 significantly antagonized the protocatechuic acid-induced analgesia in the tail-immersion and writhing tests, whereas pre-treatment of CB2 receptor antagonist AM630 was found to be effective only in the tail-immersion test.
Conclusion
It is concluded that cannabinoid modulation contributes to the analgesic effect of protocatechuic acid in spinal level rather than peripheral. CB1 receptor stimulation rather than CB2 receptor stimulation mediates the analgesic effect of protocatechuic acid in both levels, especially peripheral.
Graphical abstract
Protocatechuic acid inhibits pain response via cannabinoidergic system
Review: The nicotinic modulation of pain Bektas, Nurcan; Nemutlu, Dilara; Cam, Mevcude ...
Pakistan journal of pharmaceutical sciences
33, Issue:
1
Journal Article
Peer reviewed
Pain is a physiological unpleasant sensation that associated with actual or potential tissue damage and affects the major part of human population. Numerous modulatory system control pain through a ...complex process. The drugs that regulate the modulators involving in this process are currently available; however, the studies to understand the process and develop new agents are still going on. In this review, it is aimed to relay information about how nicotinic receptors contribute the pain modulation. It is obvious that a wide variety of nicotinic receptors is located in both peripheral and central areas. Among these receptors α7, α4β2 and α9α10 receptor subtypes draw attention in terms of pain modulation. The fact that different receptor subtypes involve in different processes of different pain conditions leads to provide beneficial results from the agonism of α7, α4β2 and antagonism of α9α10. The major restraint of the usage of nAChR agonists is their adverse effects. However, nowadays, the side effects are reduced by the clinical developments. Additionally, positive allosteric modulators that amplify the effectiveness of nAChR ligands are in demand.
Nicotine acts as an agonist of nicotinic acetylcholine receptors (nAChR). These receptors belong to a superfamily of ligand-gated ion channels. We previously demonstrated that nicotine increased ...electrical field stimulation (EFS)-induced contractile or relaxation responses, possibly by facilitating neurotransmitter release from nerve terminals in various rabbit tissues. Studies have shown that there is an interaction between the endocannabinoid and nicotinic systems. This study aimed to investigate the interaction between nicotine and the endocannabinoid system in the rabbit urine bladder and also investigate the enhancing effect of nicotine on EFS-induced contractile responses in rabbit isolated bladder smooth muscle and its interaction with the endocannabinoid system.
The New Zealand albino male adult rabbits were used for this study. Following scarification, the urine bladder was rapidly excised, and then uniform strips were prepared. Each strip was mounted under 1 g isometric resting tension in an organ bath containing 20 mL of Krebs-Henseleit solution. After obtaining EFS-induced contractile responses, 10-4 M concentrations of nicotine were applied to the preparations, and EFS was stopped after 5 stimulations. Following washing, the same experimental procedure was performed with the same tissue in the presence of AM251 (a cannabinoid CB1R antagonist, 10-6 M), AM630 (a cannabinoid CB2R antagonist, 10-6 M), and capsazepine (a vanilloid receptor antagonist, 3 × 10-6 M).
Nicotine enhanced the EFS-induced contraction responses by 17.16% ± 2.81% at a 4-Hz stimulation frequency. Cannabinoid receptor antagonists AM251 and AM630 reduced this increasing effect of nicotine although it was not significant and vanilloid receptor antagonist capsazepine did not significantly alter the nicotines' effect.
These results show that enhancing effect of nicotine in the smooth muscle of the rabbit bladder, even though it was not significant endocannabinoid system possibly have a role in nicotines' effect.
Aripiprazol; çeşitli afektif bozuklukların tedavisinde kullanılan ve özgün bir etki mekanizmasına sahip atipik antipsikotik ilaçtır. Tetiklediği mekanizmalardan hareketle kronik ağrı kontrolünde ...etkin bir tedavi sağlayabileceği düşünülmektedir. Bu tez çalışmasında, aripiprazolün nöropatik ağrı ve fibromiyalji üzerine olası etkisinin araştırılması amaçlandı. Bu amaçla; nöropatik ağrı üzerine etkinin değerlendirilmesi için kronik konstriksiyon hasarı ile indüklenen nöropatik ağrı modeli ve fibromiyalji üzerine etkinin değerlendirilmesi için rezerpin ile indüklenen fibromiyalji modeli olmak üzere iki farklı deneysel modelde intraperitoneal (i.p.) olarak uygulanan 1, 5 ve 10 mg/kg aripiprazolün olası antiallodinik etkisi elektronik von Frey cihazı ile değerlendirildi ve referans ilaçlar olarak sırasıyla 30 mg/kg pregabalin ve 30 mg/kg duloksetin etkileri ile karşılaştırıldı. Ayrıca her iki modelde de oluşturulan iki gruba aripiprazol ile referans ilaçların kombine uygulaması yapılarak kombinasyonun sağlayabileceği avantaj araştırıldı. Aripiprazolün, nöropatik ağrı üzerinde 5 ve 10 mg/kg dozlarda, fibromiyalji üzerinde ise tüm dozlarda antiallodinik etki gösterdiği belirlendi. Ayrıca mevcut tedavilere kombine edilmesi daha düşük dozla etkin tedavi sağlanmasına olanak tanıdı. Bu tez çalışması, nöropatik ağrı ve fibromiyalji tedavilerinde yeni tedavi yaklaşımlarına katkıda bulunacak preklinik veriler sunmaktadır.
PDF
